Familial hypercholesterolemia - heterozygous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with HeFH (n = 58) had higher levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, Lp(a), and apoB, whereas patients with CHL phenotype (n = 39) had higher levels of triglycerides and lower high-density lipoprotein (HDL)-cholesterol levels.
|
30956097 |
2020 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
New therapies such as mipomersen, a second-generation antisense oligonucleotide, microsomal triglyceride transfer protein inhibitors that decrease the synthesis of apolipoprotein B-containing lipoproteins and proprotein convertase subtilisin/kexin type 9 inhibitors hold promise in reducing cholesterol levels in those patients in whom low density lipoprotein cholesterol (LDL-C) reduction is required beyond the use of statins, especially in those with severe heterozygous familial hypercholesterolaemia or homozygous familial hypercholesterolaemia.
|
24870549 |
2014 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present data from a cohort of 611 patients referred with suspected heterozygous familial hypercholesterolaemia (FH) from five UK lipid clinics, who were initially screened for point mutations in LDLR and the common APOB and PCSK9 mutations.
|
19538517 |
2009 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The children with heFH with a family history of pCAD had higher LDL cholesterol and apolipoprotein B levels and greater aIMT and cIMT than those with negative family history.
|
19446849 |
2009 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to assess femoral atherosclerosis by ultrasound in patients with molecularly defined heterozygous familial hypercholesterolemia (FH) in comparison with matched control subjects and in relation to mutational class in the LDL receptor and apolipoprotein B (APOB) genes.
|
18096825 |
2008 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated effects of cholesterol lowering by therapeutic intervention (2 years) with atorvastatin (80 mg daily) and simvastatin (40 mg daily) on circulating oxidized LDL (absolute level and in proportion to plasma apolipoprotein B) in relation to atherosclerosis progression (carotid intima-media thickness, carotid IMT) and to inflammation (high-sensitivity C-reactive protein, hsCRP) in 115 stable patients with heterozygous familial hypercholesterolemia (FH).
|
16005883 |
2006 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fasting plasma concentrations of apoB-48 and RLP-C were measured in 15 subjects with heterozygous FH and 15 age- and sex-matched, normolipidaemic subjects.
|
11168448 |
2001 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of low-density lipoprotein apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia.
|
11297603 |
2001 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study.
|
7755658 |
1995 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The eight-member kindred ascertained through this subject who presented with both a clinical phenotype of FH and the FDB apo B-100 (Arg3500----Gln) mutation was studied.
|
1505645 |
1992 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metabolic pathways of apolipoprotein B in heterozygous familial hypercholesterolemia: studies with a [3H]leucine tracer.
|
1770302 |
1991 |
Familial hypercholesterolemia - heterozygous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia. Effects on kinetics of apolipoprotein B.
|
2912427 |
1989 |